
    
      A Phase I/II, Open-Label, Multicenter Study to Assess the Safety, Tolerability,
      Pharmacokinetics and Anti-tumor Efficacy of DZD9008 in Patients with Advanced Non-Small Cell
      Lung Cancer (NSCLC) with EGFR or HER2 mutation. This study includes dose escalation, dose
      expansion, food effect (Part A) and dose extension (Part B).
    
  